Candel Therapeutics, Inc. (CADL) Misses Q3 EPS by 3c

Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q3 EPS of ($0.21), $0.03 worse than the analyst estimate of ($0.18).

For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.

You May Also Be Interested In

• Abercrombie & Fitch (ANF) Tops Q2 EPS by $2.19, Offers Guidance
• Movado Group (MOV) Tops Q2 EPS by 19c, Beats on Revenue; Offers Guidance
• Zhihu Inc. (ZH) Reports Q2 Revenue Below Estimates